We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer’s business, however, the current proposal significantly undervalues our company and also does not adequately address or provide reassurance for some of the potential financing and regulatory execution risks related to the acquisition.